About: The MiR-17-92 Gene Cluster is a Blood-based Marker for Cancer Detection in Non-small-cell Lung Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The MiR-17-92 Gene Cluster is a Blood-based Marker for Cancer Detection in Non-small-cell Lung Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The MiR-17-92 Gene Cluster is a Blood-based Marker for Cancer Detection in Non-small-cell Lung Cancer
Creator	Ma, Zhongliang Cn, Be, Jia Jia, Xiaoyu Ma, ，zhongliang Phd, Qiangling Phd, Zhongliang Road, West Sun, Qiangling Yang, Chenghao Zhou, Jinbao
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Lung cancer is one of the most malignant cancers threatening human health. The miR-17-92 gene cluster is a highly conserved oncogene cluster encoding six miRNAs: miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92a. This study explored whether these miRNAs can be used as diagnostic markers for non-small-cell lung cancer (NSCLC). METHODS: Serum samples were collected from healthy subjects (n = 23) and NSCLC patients at various stages (n = 74). Serum RNA was extracted by the TRIzol-glycogen method, and cDNA libraries were constructed by reverse transcription. Quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to detect the expression levels of the 6 miRNAs. RESULTS: The expression levels of the six miRNAs varied in different stages of NSCLC. Thus, two receiver operating characteristic (ROC) curves, i.e., normal subjects and stage I-III patients and normal subjects and stage IV patients, of each miRNA were established to determine the interval of normal ΔCt values. The two areas under the curve (AUCs) of each miRNA were investigated (miR-17: 0.8097 and 1.000; miR-18a: 0.7388 and 0.9907; miR-19a/19b: 0.8451 and 0.5104; miR-20a: 0.8975 and 1.000; miR-92a: 0.8097 and 0.8342). In addition, a high positive correlation was discovered between miR-17 and miR-20a expression. Combining these two miRNAs can improve the screening effect of NSCLC. CONCLUSION: The miR-17-92 gene cluster can likely serve as a diagnostic marker in NSCLC.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1016/j.amjms.2020.05.004
bibo:pmid	32466856
has license	no-cc
sha1sum (hex)	16a363e36b995c059b697ed430ac0a107b0f3fae
schema:url	https://doi.org/10.1016/j.amjms.2020.05.004
resource representing a document's title	The MiR-17-92 Gene Cluster is a Blood-based Marker for Cancer Detection in Non-small-cell Lung Cancer
has PubMed Central identifier	PMC7211762
has PubMed identifier	32466856
schema:publication	Am J Med Sci
resource representing a document's body	covid:16a363e36b995c059b697ed430ac0a107b0f3fae#body_text
is schema:about of	named entity 'Lung Cancer' named entity 'CANCERS' named entity 'BLOOD' named entity 'MIR-17-92' named entity 'gene' named entity 'miR-17' named entity 'miRNAs' named entity 'highly conserved' named entity 'malignant' named entity 'Cancer Detection' named entity 'MiR-17' named entity 'stage IV' named entity 'NSE' named entity 'NSCLC' named entity 'NSCLC' named entity '5-year survival rate' named entity '5-year survival rate' named entity 'non-small-cell lung cancer' named entity 'reverse transcription' named entity 'abscissa' named entity 'biomarkers' named entity 'ROC' named entity 'A549' named entity 'oncogenes' named entity 'miRNAs' named entity 'mortality rate' named entity 'miR-17' named entity 'stage IV' named entity 'ROC' named entity 'enzyme' named entity 'downregulated' named entity 'antigen' named entity 'miR' named entity 'Beijing' named entity 'upregulation' named entity 'NSCLC' named entity 'China' named entity 'NSCLC' named entity 'PCR' named entity 'qRT-PCR' named entity 'ROC' named entity 'significant difference' named entity 'miRNAs' named entity 'miR-17' named entity 'stage IV' named entity 'Ca125' named entity 'sensitivity and specificity' named entity 'NSCLC' named entity 'qRT-PCR' named entity 'miRNA' named entity 'miRNA' named entity 'stage IV' named entity 'ROC' named entity 'miRNAs' named entity 'miRNA' named entity 'miRNA' named entity 'NSCLC' named entity 'miRNAs' named entity 'downregulated' named entity 'stage IV' named entity 'developing countries' named entity 'miR-17' named entity 'qRT-PCR' named entity 'spiral computed tomography' named entity 'late-stage' named entity 'RNase' named entity 'miR-17' named entity 'sensitivity and specificity' named entity 'liver cancer' named entity 'lung cancer' named entity 'ROC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software